---
title: "Sarepta reports a second death case related to its gene therapy"
description: "Sarepta Therapeutics reported a second death case related to its gene therapy, with a patient receiving Elevidys treatment dying from acute liver failure. Three months ago, another teenage boy also di"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/244583352.md"
published_at: "2025-06-15T13:56:21.000Z"
---

# Sarepta reports a second death case related to its gene therapy

> Sarepta Therapeutics reported a second death case related to its gene therapy, with a patient receiving Elevidys treatment dying from acute liver failure. Three months ago, another teenage boy also died from the same treatment. Both cases involved patients with Duchenne muscular dystrophy who were unable to walk. The company has suspended the relevant clinical trials and stopped providing the drug to such patients, and is considering strengthening the immunosuppressive regimen

Sarepta Therapeutics announced that another patient receiving its gene therapy for rare muscle diseases has died from acute liver failure. The company stated that this death occurred in a patient who received the one-time treatment drug Elevidys, and three months ago, a teenage boy died after receiving the treatment. Both cases involved patients with Duchenne muscular dystrophy who were unable to walk. The company has suspended a clinical trial, stopped shipping the drug to patients who cannot walk, and is considering strengthening the immunosuppressive regimen for these patients

### Related Stocks

- [SRPT.US - Sarepta Therap](https://longbridge.com/en/quote/SRPT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Sarepta rises on NZ regulatory nod to start Huntington's disease trial | Sarepta Therapeuticsshares rose 3% to $20.92 in premarket trading after receiving regulatory approval in New Zealand to  | [Link](https://longbridge.com/en/news/274824082.md) |
| Forecasting The Future: 8 Analyst Projections For Sarepta Therapeutics | During the last three months, 8 analysts evaluated Sarepta Therapeutics (NASDAQ:SRPT), showing a range of bullish to bea | [Link](https://longbridge.com/en/news/272548848.md) |
| Tempered Growth Outlook and Heightened Regulatory Risk Drive Sell Rating on Sarepta Therapeutics | Needham analyst Gil Blum has reiterated a Sell rating on Sarepta Therapeutics (SRPT) due to concerns over its growth out | [Link](https://longbridge.com/en/news/272438221.md) |
| Sarepta Therapeutic Q4 prelim net product revenue misses estimates | Sarepta Therapeutics reported preliminary Q4 net product revenue of $369.6 million, missing analyst estimates of $382.07 | [Link](https://longbridge.com/en/news/272301526.md) |
| JPM26: Sarepta CEO touts “avalanche of Elevidys data” amid 2025 safety woes | Sarepta's CEO Douglas Ingram presented at the J.P. Morgan Healthcare Conference, discussing the challenges faced by Elev | [Link](https://longbridge.com/en/news/272413649.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.